Dubai, Oct. 19, 2025 (GLOBE NEWSWIRE) — Vantage Drilling International Ltd. (the “Company”) announces the immediate termination of the contract for the Platinum Explorer for its approximately 260-day campaign. The termination is due to changes in economic sanctions applicable to the campaign, rendering the contract execution unlawful and therefore subject to termination. This information has been submitted pursuant to Section 5-12 of the Norwegian Securities Trading Act and MAR Article 17. The information was submitted for publication at 2025-10-19 at 7:30 CEST. About the Company Vantage Drilling International Ltd., a Bermuda exempted company, is an offshore drilling contractor. Vantage Drilling’s primary business is to contract drilling units, related equipment and work crews primarily on a dayrate basis to drill oil and...

PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC)1Most patients with mHSPC progress to metastatic castration-resistant prostate cancer, underscoring urgent need for new therapies that can reduce risk of progression in earlier disease settings2,3The safety profile and tolerability of Pluvicto in this third positive Phase III study were consistent with its established profile in PSMAfore and VISION trials1,4,5Novartis plans to submit to regulatory authorities by end of year; potential approval would double the number of patients eligible for Pluvicto and further establish its efficacy in metastatic prostate cancer settingsBasel, October 19, 2025 – Novartis...

Median progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS follow up suggesting a more than doubling of the benchmark PFS and a disease control rate of 91% No maximum tolerated dose reached despite dosing up to 385 mg/m² (approximately 4x conventional doxorubicin dose) with no severe cardiac toxicity observed even at cumulative doses up to 550 mg/m² LONDON and PHILADELPHIA, Oct. 19, 2025 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION®, a unique oncology delivery platform, today announces further development updates in the Phase 1a clinical trial with its lead program, faridoxorubicin (FAP-Dox, AVA6000) to be presented at the 2025 European Society of Medical Oncology Annual...

WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was presented by Caroline Robert, M.D., Ph.D., at the European Society for Medical Oncology (ESMO) Congress 2025 being held in Berlin (Poster 1644P). The analysis of acral melanoma patients from the IGNYTE clinical trial showed treatment with RP1 combined with nivolumab resulted in an objective response rate of 44% (8/18) with a median duration of response of 11.9 months (3.9, not reached). The safety profile was favorable with generally transient grade 1 and 2 treatment related adverse events. Acral melanoma is a rare and aggressive type of cutaneous...

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that the Company plans to report topline data from the Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneous Urticaria (CSU) conducted by its partner, Shanghai Jeyou Pharmaceutical Co., Ltd. (Jeyou), formerly called Shanghai Jemincare Pharmaceutical Co., Ltd., in a premarket press release and webcast on Monday, October 20, 2025. RAPT will host a webcast conference call accompanied by a slide presentation on Monday, October 20, 2025 at 8:30 a.m. ET. To join the conference call via phone and participate...

CHENNAI, India, Oct. 18, 2025 (GLOBE NEWSWIRE) — Sify Technologies Limited (NASDAQ: SIFY), India’s leading Digital ICT solutions provider with global service capabilities spanning Data Center, Cloud, Networks, Security and Digital services, today announced that it will report its unaudited IFRS financial results for the second quarter ended September 30, 2025 on Saturday, October 25, 2025 before the market opens.  The following Monday, October 27, 2025, Sify will host a conference call at 8:30 AM ET with Mr. Raju Vegesna, Chairman of the Board and Mr. M P Vijay Kumar, Executive Director & Group CFO. Interested parties may participate by dialling +1-888-506-0062 (Toll Free in the U.S. or Canada) or +1-973-528-0011 (International), which will also be simultaneously broadcast live over the Internet at www.sifytechnologies.com/investors...

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) — The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in Etoiles Capital Group Co., Ltd. (Nasdaq: EFTY) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in EFTY from 04:00:00 on October 6, 2025 to 23:59:00 on October 17, 2025. The last sale price of the company’s ordinary shares was $15.02.  More information about the SEC’s order can be found at https://www.sec.gov/files/litigation/suspensions/2025/34-104163.pdf. Trading will remain halted until Etoiles Capital Group Co., Ltd. has fully satisfied Nasdaq’s request for additional information. For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM...

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) — The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in Platinum Analytics Cayman Limited (Nasdaq: PLTS) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in PLTS from 04:00:00 on October 6, 2025 to 23:59:00 on October 17, 2025. The last sale price of the company’s ordinary shares was $17.50.  More information about the SEC’s order can be found at https://www.sec.gov/files/litigation/suspensions/2025/34-104164.pdf. Trading will remain halted until Platinum Analytics Cayman Limited has fully satisfied Nasdaq’s request for additional information. For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM...

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) — The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in Pitanium Limited (Nasdaq: PTNM) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in PTNM from 04:00:00 on October 6, 2025 to 23:59:00 on October 17, 2025. The last sale price of the company’s ordinary shares was $10.39.  More information about the SEC’s order can be found at https://www.sec.gov/files/litigation/suspensions/2025/34-104165.pdf. Trading will remain halted until Pitanium Limited has fully satisfied Nasdaq’s request for additional information. For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site. For...

NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell Death Data Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738 BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) presented data at the European Society for Medical Oncology Congress 2025 (“ESMO”) on a new model system investigating the synergistic effects of NUC-7738 and PD-1 inhibition in primary organoids derived from patients with renal cell carcinoma (“RCC”). Using patient-derived organoids (“PDOs”) from ten patients with RCC and autologous tumor-infiltrating lymphocytes (“TILs”), co-culture experiments reveal that NUC-7738 enhances the effectiveness of PD-1 inhibitors, resulting in increased tumor cell killing. This combinatorial approach may offer a new option for cancers that no longer...